These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 32128620)
1. Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS. Cha DI; Choi GS; Kim YK; Kim JM; Kang TW; Song KD; Ahn SH Eur Radiol; 2020 Jul; 30(7):3723-3734. PubMed ID: 32128620 [TBL] [Abstract][Full Text] [Related]
2. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions. Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947 [TBL] [Abstract][Full Text] [Related]
3. Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System. Min JH; Kim JM; Kim YK; Kang TW; Lee SJ; Choi GS; Choi SY; Ahn S Hepatology; 2018 Dec; 68(6):2254-2266. PubMed ID: 30070365 [TBL] [Abstract][Full Text] [Related]
4. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI. Song JS; Choi EJ; Hwang SB; Hwang HP; Choi H Eur Radiol; 2019 Jan; 29(1):401-410. PubMed ID: 29922928 [TBL] [Abstract][Full Text] [Related]
5. Magnetic Resonance Imaging With Extracellular Contrast Detects Hepatocellular Carcinoma With Greater Accuracy Than With Gadoxetic Acid or Computed Tomography. Min JH; Kim JM; Kim YK; Cha DI; Kang TW; Kim H; Choi GS; Choi SY; Ahn S Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2091-2100.e7. PubMed ID: 31843599 [TBL] [Abstract][Full Text] [Related]
6. Liver Imaging Reporting and Data System on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging. Cha DI; Jang KM; Kim SH; Kang TW; Song KD Eur Radiol; 2017 Oct; 27(10):4394-4405. PubMed ID: 28374073 [TBL] [Abstract][Full Text] [Related]
7. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Lee S; Kim SS; Chang DR; Kim H; Kim MJ Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765 [TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy? Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276 [TBL] [Abstract][Full Text] [Related]
9. Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Lee S; Kim MJ; Kim SS; Shin H; Kim DY; Choi JY; Park MS; Mitchell DG Hepatol Int; 2020 Jan; 14(1):70-79. PubMed ID: 31802388 [TBL] [Abstract][Full Text] [Related]
10. EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC. Min JH; Kim JM; Kim YK; Kim H; Cha DI; Kang TW; Choi GS; Choi SY; Ahn S Liver Int; 2021 Dec; 41(12):2986-2996. PubMed ID: 34242468 [TBL] [Abstract][Full Text] [Related]
11. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria. Zhang Y; Tang W; Xie S; Chen J; Zhang L; Rong D; Kuang S; He B; Wang J Eur Radiol; 2021 Oct; 31(10):7715-7724. PubMed ID: 33782766 [TBL] [Abstract][Full Text] [Related]
12. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI? Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467 [TBL] [Abstract][Full Text] [Related]
13. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma. Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603 [TBL] [Abstract][Full Text] [Related]
14. Intra-individual comparison of gadolinium-enhanced MRI using pseudo-golden-angle radial acquisition with gadoxetic acid-enhanced MRI for diagnosis of HCCs using LI-RADS. Kim YC; Min JH; Kim YK; Lee SJ; Ahn S; Kim E; Peeters H Eur Radiol; 2019 Apr; 29(4):2058-2068. PubMed ID: 30324388 [TBL] [Abstract][Full Text] [Related]
15. Liver imaging reporting and data system diagnostic performance in hepatocellular carcinoma when modifying the definition of "washout" on gadoxetic acid-enhanced magnetic resonance imaging. Hu W; Lyu R; Wang D; Gao Z; Sun C; Jia K Arab J Gastroenterol; 2024 Feb; 25(1):58-63. PubMed ID: 38245474 [TBL] [Abstract][Full Text] [Related]
16. Intraindividual Comparison of Hepatocellular Carcinoma Washout between MRIs with Hepatobiliary and Extracellular Contrast Agents. Kim YY; Kim YK; Min JH; Cha DI; Kim JM; Choi GS; Ahn S Korean J Radiol; 2021 May; 22(5):725-734. PubMed ID: 33660458 [TBL] [Abstract][Full Text] [Related]
17. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients. Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914 [No Abstract] [Full Text] [Related]
18. Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates. Oh NE; Choi SH; Kim S; Lee H; Jang HJ; Byun JH; Won HJ; Shin YM Eur Radiol; 2024 Jan; 34(1):465-474. PubMed ID: 37532900 [TBL] [Abstract][Full Text] [Related]
19. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI. Huang P; Zhou C; Wu F; Xiao Y; Qian X; Wang Y; Yang C; Zeng M Eur Radiol; 2023 Apr; 33(4):2735-2745. PubMed ID: 36472696 [TBL] [Abstract][Full Text] [Related]
20. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features. Wang D; Zhang Y; Lyu R; Jia K; Xu PJ Abdom Radiol (NY); 2024 Sep; 49(9):3045-3055. PubMed ID: 38605217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]